Page 154 - மையங்கள் க்கு மருத்துவ மருத்துவ உதவி சேவைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Natera Inc (NASDAQ: NTRA)Cassava Sciences Inc First, we have the clinical-stage biopharmaceutical company, Cassava. The company focuses on developing drugs for the treatment of nervous system disorders. Cassava is currently in focus due to the spotlight on the treatment of Alzheimer’s disease. This comes after Biogen Inc (NASDAQ: BIIB) received an accelerated FDA approval for its drug ADUHELM™. So, investors appear to be optimistic that Cassava’s simufilam and SavaDx may benefit from this development.   Simufilam is Cassava’s lead drug candidate to treat Alzheimer’s disease while SavaDx is an investigational diagnostic candidate to detect Alzheimer’s. The company will be presenting its results of an interim analysis on safety and cognition for the first 50 subjects to complete 9 months of open-label drug treatment. These data will be presented at the 2021 Alzheimer’s Association International Conference (AAIC) in Denver scheduled for 26th to

United statesLaboratory testVir biotechnology incCassava sciences incTop health care stocks to watch rightAlzheimer association international conferenceBiogen incDigital international liver congressPfizer incEuropean unionModerna incResearch internationalCommittee for medicinal products human useCenters for medicare medicaid servicesDrug administrationFocusnatera inc